Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Xingsheng Hu1*, Ke Pu2*, Xuqin Feng1, Shimin Wen1, Xi Fu1, Cuihua Guo1, Wenwu He3*

1 Department of Oncology, Nanchong Central Hospital (The Second Clinical College of North Sichuan Medical College), Nanchong, China, 2 DaZhou College of Chinese Medicine, DaZhou, China, 3 Department of Cardiothoracic Surgery, Nanchong Central Hospital, Nanchong, China

☯ These authors contributed equally to this work.
* 137666745@qq.com.

Abstract

Background
Gemcitabine and pemetrexed have been used as maintenance therapy. However, few systematic reviews and meta-analyses have assessed their effects in the newest studies. This systematic review and meta-analysis were conducted to assess the role of gemcitabine and pemetrexed in the maintenance treatment of non-small-cell lung carcinoma (NSCLC).

Methods
We performed a literature search using PubMed, EMBASE and Cochrane library databases from their inceptions to September 16, 2015. We also searched the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN) databases from 2008 to 2015. Two authors independently extracted the data. The Cochrane Collaboration’s risk of bias graph was used to assess the risk of bias. The GRADE system was used to assess the grading of evidence, and a meta-analysis was conducted using Stata 11.0 software.

Results
Eleven randomized controlled trial (RCT) studies were collected. Ten studies were included in the meta-analysis and divided into the following 4 groups: gemcitabine vs. best supportive care (BSC)/observation, pemetrexed vs. BSC/placebo, pemetrexed + bevacizumab vs. bevacizumab and pemetrexed vs. bevacizumab. Gemcitabine exhibited significantly improved progression-free survival (PFS) compared with BSC (hazard ratio (HR) = 0.62, p = 0.000). Pemetrexed exhibited significantly improved PFS (HR = 0.54, p = 0.000) and OS (HR = 0.75, p = 0.000) compared with BSC. Pemetrexed + bevacizumab almost exhibited significantly improved PFS (HR = 0.71, p = 0.051) compared with bevacizumab.
Pemetrexed exhibited no improvement in PFS or overall survival (OS) compared with bevacizumab. Regarding the grade, the GRADE system indicated that the gemcitabine group was "MODERATE", the pemetrexed group was "HIGH", and both the pemetrexed + bevacizumab vs. bevacizumab groups and pemetrexed vs. B groups were "LOW".

**Conclusions**

Gemcitabine or pemetrexed compared with BSC/observation/placebo significantly improved PFS or OS. Whether pemetrexed + bevacizumab compared with bevacizumab alone significantly improves PFS requires further investigation.

**Introduction**

Lung cancer is the leading cancer in both incidence and mortality and accounts for 25% of all cancer deaths [1]. Additionally, the incidence of lung cancer is increasing in some regions. Non-small-cell lung carcinoma (NSCLC) accounts for greater than 80% of all lung cancers. In the past decades, the standard first-line treatment for advanced NSCLC consisted of platinum-based doublet therapy for no more than six cycles [2]. However, there is generally a brief period of disease control after the response to first-line chemotherapy, and most of patients will die because of disease progression. Thus, the 5-year survival rate is very low (less than 5%) [3, 4, 5]. Consequently, it is necessary to identify more effective and tolerable treatments to delay progression and improve survival in advanced-stage NSCLC.

Maintenance therapy is one strategy that has been investigated extensively in recent years. Currently, only two chemotherapy agents have been recommended for advanced NSCLC by National Comprehensive Cancer Network (NCCN) guidelines, gemcitabine and pemetrexed. Several RCTs have demonstrated that gemcitabine [6, 7] or pemetrexed [8, 9, 10] compared with BSC/placebo improves PFS and that pemetrexed improves OS more effectively. However, few systematic reviews or meta-analyses have analyzed these newest RCTs. In his meta-analysis, Behera [11] pooled different therapeutic approaches and incorporated the overall HR for gemcitabine, pemetrexed, and other chemotherapy agents, such as epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Soon [12] also indiscriminately mixed different maintenance treatment agents, including different first-line chemotherapy programs, to incorporated an overall HR. Apparently, these analyses were not accurate or objective, confusing the efficiency of the single therapeutic agents. Regarding gemcitabine, Zhang [13] conducted a meta-analysis including three gemcitabine trials (Brodowicz [6], Belani [14] and Perol [15] (the Perol [15] trial was only an abstract)), and the data were not mature. Regarding pemetrexed, Qi [16] conducted a meta-analysis of pemetrexed vs. placebo to assess PFS and only included two studies (Ciuleanu [8] and Paz-Ares [17] (the Paz-Ares study was only an abstract)), and the OS data were not mature. Thus, a meta-analysis for OS comparison was not conducted. In addition, in the recent 3 years, other evidence of pemetrexed maintenance therapy has emerged. Pemetrexed + bevacizumab compared with bevacizumab alone improves PFS but did not improve OS [18, 19, 20]. Therefore, there is a great need to conduct a systematic review and meta-analysis to assess these up-to-date studies.

In this systematic review and meta-analysis, we updated the Perol (2010) study [15] to Perol (2012) [7] as well as Paz-Ares (2011) [17] to Paz-Ares (2012) [9] (to Paz-Ares (2012) [9, 2013] [10]) by pooling the pemetrexed ± bevacizumab vs. bevacizumab analyses, and collected data from other studies on
pemetrexed vs. docetaxel in maintenance therapy. More importantly, we used the Cochrane Collaboration tool to assess the risk of bias and the GRADE system to assess the grade of evidence.

Materials and Methods

Study design

This systematic review and meta-analysis strictly followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines 2009 [21]. Except for Brodowic [6], Belani [14] and Karayama [22] studies, all of the other studies have protocols, which were available from https://clinicaltrials.gov.

Eligibility criteria

The following study selection criteria were applied: (1) population: patients were pathologically diagnosed with advanced chemotherapy-naïve NSCLC; (2) intervention: gemcitabine or pemetrexed as a single agent was applied in maintenance therapy after 4 to 6 cycles of induction chemotherapy; (3) comparison: no restrictions were imposed and included BSC/observation, cytotoxic agents, vascular endothelial growth factor receptor (VEGFR), EGFR-TKI or any other therapeutic drugs; (4) outcomes: HR of PFS and OS, risk ratios (RR) of grade 3–4 adverse events (AEs); (5) study design: only RCTs were eligible.

Literature search

Electronic databases, including PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL), were searched for relevant clinical trials published from their inceptions to September 16, 2015. The following key words were applied: (1) "lung cancer gemcitabine maintenance" and (2) "lung cancer pemetrexed maintenance". After the first search, article types were chosen as follows: "clinical trial" was chosen in PubMed, "randomized control trials" was chosen in EMBASE, and no restrictions were imposed in the Cochrane library. Additionally, no language restrictions were imposed. Furthermore, we screened the references from the retrieved original articles and screened the ASCO, ESMO, and NCCN databases between 2008 and 2015 to identify any other potentially eligible studies.

Study selection

The selection of trials main was accorded to eligibility criteria. This process were performed by two authors and blinded. The meeting abstracts fulfilling the criteria were also included. The references were screened from titles and further selected by reading the abstracts.

Data extraction and items

Two reviewers independently extracted the following data from each eligible study: first author’s last name and year of publication, trial’s name and registration number, number of patients, region and race, histology, the drugs of induction and maintenance therapy, HR of PFS and OS, and the incidence of grade 3–4 AEs. Any disagreements were resolved by consensus or consultation with a third reviewer.

Assessing the risk of bias and grading the quality of evidence

According to the new Cochrane handbook (version 5.1.0), which no longer recommends any quality assessment tables or checklists to assess the quality of original articles, the Cochrane
Collaboration’s tool was adopted to assessing the risk of bias [23], and the GRADE system was used to assess the grades of evidence [24]. The assessment for the risk of bias was strictly performed according to the guidelines outlined in the Cochrane handbook. Two investigators objectively reviewed all of the studies and assigned a value of “low”, “unclear” or “high” to the following six domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. All of the open-label trials were judged as “high risk” in the blinding of participants (performance bias) and researchers as well as blinding of the outcome assessment (detection bias).

The GRADE system identified the following four grades to rate the quality of evidence [25]: (1) high: further research is very unlikely to change the estimate of the effect; (2) moderate: further research is likely to impact the estimate of the effect and may change the estimate; (3) low: further research is very likely to impact the estimate of the effect and is likely to change the estimate; and (4) very low: any estimate of the effect is very uncertain.

Statistical analysis

We estimated HRs and 95% confidence intervals (CIs) for PFS and OS and the RR for the grade 3–4 AEs. Heterogeneity was determined using the chi-squared-based Cochran’s Q statistic and I² statistic. I² values of 0–40%, 40–70% and 70–100% were used to represent low, moderate and high variance, respectively [26]. If moderate heterogeneity existed or different clinical characteristics were noted, the random-effects model was used. Otherwise, the fixed-effects model was used. If significant heterogeneity was identified, subgroup analysis or sensitivity analyses were conducted. Potential publication bias was evaluated by funnel plots and Egger’s weighted linear regression test. RevMan 5.3 was used to generate the figure of the "Cochrane Collaboration’s tool for assessing risk of bias". The GRADE profiler software (version 3.6) (available at: http://www.grade/workinggroup.org/) was used to assess the grades of evidence. All of the other statistical data analyses were performed using Stata 11.0. All of the p-values were two-sided and were considered statistically significant at the 0.05 level.

Results

Study selection and characteristics

Three hundred four relevant citations were identified at the initial search stage. Finally, 11 studies were included in this systematic review, and 10 studies were included in the meta-analysis. These studies were divided into the following 4 groups: gemcitabine vs. BSC/observation, pemetrexed vs. BSC±placebo, pemetrexed +bevacizumab vs. bevacizumab, and pemetrexed vs. bevacizumab. Other studies concerning pemetrexed vs. docetaxel were qualitatively analyzed separately. The flow diagram of the literature retrieval and selection is presented in Fig 1.

The main characteristics of all of the eligible RCTs are presented in Tables 1 and 2. Except for the Mubarak [27] and Karayama [22] were multicenter phase II clinical trials, all of the other studies were multicenter phase III clinical trials. The Ciuleanu [8] and Paz-Ares [9, 10] studies involved randomized, double-blind trials, whereas the Perol [7], Mubarak [26], Patel [20], Barlesi [18, 19], Zinner [28], Galetta [29] and Karayama [29] studies were randomized, open-label trials. Only the Brodowicz trial did not describe whether it was a double-blind or open-label trial.

Risk of bias and grades of evidence

The results for assessing the risk of bias are shown in Fig 2, and the grades of evidence are presented in Tables 3–6. Two double-blind trials offered better descriptions of random sequence
generation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessment. All of the open-label trials did not describe the details of allocation concealment, and, more importantly, their main bias was the lack of blinding.

**PFS**

The meta-analysis pooled results are presented in Fig 3. The heterogeneity test indicated that a random-effects model could be selected. As a result, in the gemcitabine vs. BSC/observation group, the pooled HR was 0.62 (0.53–0.72, p = 0.000; I² = 0.0%, p = 0.318). In the pemetrexed vs. BSC ± placebo group, the pooled HR was 0.54 (0.41–0.71, p = 0.000; I² = 59.8%, p = 0.083). In the pemetrexed+ bevacizumab vs. bevacizumab group, the HR was 0.71 (0.50–1.00, p = 0.051; I² = 81.5%, p = 0.02). In the pemetrexed vs. bevacizumab group, the HR was 0.96 (0.73–1.26, p = 0.752; I² = 35.8%, p = 0.212).

**OS**

The meta-analysis pooled results are presented in Fig 4. The heterogeneity test indicated that a fixed-effects model could be selected. Thus, in the gemcitabine vs BSC/observation group, the
pooled HR was 0.91 (0.76–1.09, p = 0.314; I² = 0.0%, p = 0.856); in the pemetrexed vs BSC±placebo group, the pooled HR was 0.75 (0.65–0.87, p = 0.000; I² = 0.0%, p = 0.000); in the pemetrexed +bevacizumab vs bevacizumab group, the HR was 0.98 (0.85–1.12, p = 0.744; I² = 0, p = 0.481), in the pemetrexed vs bevacizumab group, the HR was 1.03 (0.83–1.12, p = 0.763; I² = 0, p = 0.580).

Table 1. Main characteristics of the studies.

| Study          | Study name, registration number | pts | Region and Race | Histology | Induction treatment | Maintenance treatment | HR of PFS, exp VS control | HR of OS, exp VS control |
|---------------|---------------------------------|-----|-----------------|-----------|--------------------|-----------------------|--------------------------|--------------------------|
| Brodowicz2006 | [6]                             | 206 | Europe          | NSCLC     | G                  | G+BSC VS BSC          | 0.66 (0.56–0.85)          | 0.84 (0.51–1.36)        |
| Belani2010    | [14]                            | 255 | USA, NA        | NSCLC     | G                  | G+BSC VS BSC          | -                        | 0.97 (0.72–1.30)         |
| Perol2012     | [7]                             | 464 | France, White  | NSCLC     | G                  | G VS observation      | 0.56 (0.44–0.72)          | 0.89 (0.69–1.15)         |
| Ciuleanu2009  | [8]                             | 663 | Europe, Asian  | NSCLC     | G                  | Placebo+ BSC          | p<0.0001                 | p = 0.012                |
| Perol2012     | [7]                             | 0502| White          | NSCLC     | G                  | Placebo+ BSC          | p<0.0001                 | p = 0.012                |
| Paz-Ares2012  | [9, 10]                         | 539 | Europe          | nonsquamous | PC                | P+BSC VS              | 0.62 (0.49–0.79)          | 0.78 (0.64–0.96)         |
| Mubarak2012   | [27]                            | 55  | Middle East    | nonsquamous | PC                | P + BSC               | 0.65 (0.35–1.20)          | 0.95 (0.46–1.97)         |
| Barlesi2014   | [18, 19]                        | 376 | Europe          | nonsquamous | PC+B               | P+B VS B              | 0.58 (0.45–0.76)          | 0.88 (0.64–1.22)         |
| Patel2013     | [20]                            | 939 | USA, white     | nonsquamous | PC+B               | P+B VS B              | 0.83 (0.71–0.96)          | 1.00 (0.86–1.16)         |
| Zinner2015    | [28]                            | 361 | USA, white     | nonsquamous | PC                 | P VS B                | 1.06 (0.84–1.35)          | 1.07 (0.83–1.36)         |
| NCT00762034   |                                 |     | White           | 85.7%     |                   |                       | p = 0.012                 | p = 0.949                |
| Galetta2015   | [29]                            | 118 | Italy, white   | nonsquamous | PC                 | P VS B                | 0.79 (0.53–1.17)          | 0.93 (0.60–1.42)         |
| NCT01303926   |                                 |     | White           | 89.2%     |                   |                       | p = 0.24                  | p = 0.73                 |
| Karayama2013  | [22]                            | 51  | Japan, white   | nonsquamous | PC                 | P VS D                |                          |                          |
| UMIN ID       |                                 |     | Asian           |           |                   |                       | 0.56 (0.28–1.08)          | 0.79 (0.32–2.00)         |

Pts: patients; GC: gemcitabine+cisplatin; PaC: paclitaxel+ cisplatin; DC: docetaxel+ cisplatin; PC: pemetrexed+ cisplatin; B: bevacizumab; D: docetaxel; BSC: best supportive care; exp: experiment; VS: versus; a: time from maintenance treatment; b: time from induction treatment.

doi:10.1371/journal.pone.0149247.001
Table 2. The incidence of grade 3–4 AEs.

| study            | positive | negative | positive | negative |
|------------------|----------|----------|----------|----------|
| Belani2010       | 32       | 96       | 9        | 118      |
| Perol2012        | 64       | 90       | 11       | 144      |
| Ciuleanu2009     | 70       | 371      | 9        | 213      |
| Paz-Ares2012     | 131      | 228      | 13       | 167      |
| Mubarak2012      | 4        | 24       | 4        | 23       |
| Barlesi2014      | 102      | 23       | 71       | 49       |
| Patel2013        | 366      | 76       | 310      | 133      |
| Zinner2015       | 117      | 54       | 121      | 45       |
| Galetta2015      | 13       | 47       | 22       | 36       |

doi:10.1371/journal.pone.0149247.t002

Fig 2. Risk of bias graph (a) and risk of bias summary (b).

doi:10.1371/journal.pone.0149247.g002

Caption: Risk of bias graph review authors’ judgements about each risk of bias item presented as percentages across all included studies.
### Table 3. GRADE profile evidence of the included studies for gemcitabine VS BSC/observation.

| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Pem | BSC | Relative (95% CI) | Absolute | Quality | Importance |
|---------------|--------|--------------|---------------|--------------|-------------|---------------------|-----|-----|-----------------|----------|---------|------------|
|               |        |              |               |              |             |                     |     |     |                 |          |         |            |
| progression free survival (follow-up median 20.5–25.6 months; assessed with: follow up) | 2 | randomised | serious1 | no serious | no serious | no serious | none | 0/292 | (0%) | 0/223 | (0%) | HR 0.62 | (0.53 to 0.72) | - | MODERATE | CRITICAL |
| overall survival (follow-up median 20.5–25.6 months; assessed with: follow up) | 3 | randomised | serious1 | no serious | no serious | no serious | none | 0/420 | (0%) | 0/350 | (0%) | HR 0.91 | (0.76 to 1.09) | - | MODERATE | CRITICAL |
| grade 3–4 adverse events (follow-up median 25.6 months; assessed with: observation) | 2 | randomised | serious1 | no serious | no serious | no serious | very strong association2 | 96/282 | (34%) | 20/282 | (7.1%) | RR 4.70 | (2.87 to 7.69) | 262 more per 1000 (from 133 more to 474 more) | HIGH | IMPORTANT |

1 3 study excited bias in allocation concealment and blinding  
2 1 study show RR>2, and another study show RR>5.

doi:10.1371/journal.pone.0149247.t003

### Table 4. GRADE profile evidence of the included studies for pemetrex VS BSC/placebo.

| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Pem | BSC | Relative (95% CI) | Absolute | Quality | Importance |
|---------------|--------|--------------|---------------|--------------|-------------|---------------------|-----|-----|-----------------|----------|---------|------------|
|               |        |              |               |              |             |                     |     |     |                 |          |         |            |
| progression free survival (follow-up median 11.2–12.5 months; assessed with: follow up) | 3 | randomised | no serious | no serious | no serious | increased effect for RR ~12 | 0/712 | (0%) | 0/363 | (0%) | RR 0.75 | (0.65 to 0.87) | - | HIGH | CRITICAL |
| overall survival (follow-up median 11.2–12.5 months; assessed with: follow up) | 3 | randomised | no serious | no serious | no serious | increased effect for RR ~12 | 0/712 | (0%) | 0/363 | (0%) | RR 0.75 | (0.65 to 0.87) | - | HIGH | CRITICAL |
| grade 3–4 adverse events (follow-up median 11.2–12.5 months; assessed with: observation) | 3 | randomised | no serious | no serious | no serious | very strong association3 | 205/828 | (24.8%) | 26/429 | (6.1%) | RR 3.27 | (1.56 to 6.83) | 138 more per 1000 (from 34 more to 353 fewer) | HIGH | IMPORTANT |

1 1 study inconsistency.  
2 if squamous histology, the HR will increase  
3 1 study show RR>2, and another study show RR>5.

doi:10.1371/journal.pone.0149247.t004
Table 5. GRADE profile evidence of the included studies for pemetrexed+bevacizumab VS bevacizumab.

| Quality assessment | No of patients | Effect | Quality | Importance |
|--------------------|----------------|--------|---------|------------|
|                     | Pem | B | Relative (95% CI) | Absolute |
| progression free survival (follow-up median 11.9–14.8 months; assessed with: follow up) | 2 randomised trials | serious | no serious | no serious | none | 0/567 (0%) | 0/563 (0%) | HR 0.71 (0.50 to 1.00) | - | LOW | CRITICAL |
| overall survival (follow-up median 11.9–14.8 months; assessed with: follow up) | 2 randomised trials | serious | no serious | no serious | none | 0/567 (0%) | 0/563 (0%) | HR 0.98 (0.85 to 1.12) | - | MODERATE | CRITICAL |
| “grade 3–4 adverse events” (follow-up median 11.9–14.8 months; assessed with: observation) | 2 randomised trials | serious | no serious | no serious | none | 468/567 (82.5%) | 381/563 (67.7%) | RR 1.25 (1.08 to 1.45) | 169 more per 1000 (from 54 more to 305 fewer) | LOW | IMPORTANT |

1 2 study excited bias in allocation concealment and blinding.

2 2 study excited large heterogeneity.

doi:10.1371/journal.pone.0149247.t005

Table 6. GRADE profile evidence of the included studies for pemetrex VS bevacizumab.

| Quality assessment | No of patients | Effect | Quality | Importance |
|--------------------|----------------|--------|---------|------------|
|                     | Pem | B | Relative (95% CI) | Absolute |
| progression free survival (follow-up median 27.0 months; assessed with: follow up) | 2 randomised trials | serious | no serious | no serious | none | 0/231 (0%) | 0/224 (0%) | HR 0.96 (0.73 to 1.26) | — | MODERATE | CRITICAL |
| overall survival (follow-up median 27 months; assessed with: follow up) | 2 randomised trials | serious | no serious | no serious | none | 0/231 (0%) | 0/224 (0%) | HR 1.03 (0.83 to 1.26) | — | MODERATE | CRITICAL |
| “grade 3–4 adverse events” (follow-up median 27.0 months; assessed with: observation) | 2 randomised trials | serious | no serious | no serious | none | 130/231 (56.3%) | 143/224 (63.8%) | RR 0.79 (0.49 to 1.29) | 134 fewer per 1000 (from 326 fewer to 185 fewer) | LOW | IMPORTANT |

1 2 study excited bias in allocation concealment and blinding.

2 2 study excited large heterogeneity.

doi:10.1371/journal.pone.0149247.t006
Grade 3–4 AEs

The meta-analysis pooled results are presented in Fig 5. The heterogeneity test indicated that a random-effects model could be selected. Thus, in the gemcitabine vs. BSC/observation group, the pooled HR was 4.70 (2.87–7.69, p = 0.000; $I^2 = 14.6\%$, $p = 0.279$). In the pemetrexed vs. BSC ± placebo group, the pooled HR was 3.27 (1.56–6.83, p = 0.002; $I^2 = 63.8\%$, p = 0.063). In the pemetrexed + bevacizumab vs. bevacizumab group, the HR was 1.25 (1.08–1.45, p = 0.002; $I^2 = 62.1\%$, p = 0.104). In the pemetrexed vs. bevacizumab group, the HR was 0.79 (0.49–1.29, $p = 0.343$; $I^2 = 65.7\%$, p = 0.088).

Sensitivity analysis

Sensitivity analyses were conducted on PFS and grade 3–4 AEs to assess the heterogeneity. Thus, the PFS in the Ciuleanu and Patel studies and the grade 3–4 AEs in the Patel and Zinner studies likely contributed to the heterogeneity (Figs 6 and 7).
Publication bias
Funnel plots and Egger's test were used to explore the publication bias if the value of one study was $\geq 3$. No evidence of significant publication bias was noted regarding PFS (pemetrexed vs. BSC: $p = 0.699$), OS (gemcitabine vs. BSC: $p = 0.720$; pemetrexed vs. BSC: $p = 0.652$) and AEs (pemetrexed vs. BSC: $p = 0.388$).

Discussion
Evidence Summary

Key findings and grades of evidence. In this meta-analysis, we separately conducted a meta-analysis for the gemcitabine vs. BSC/observation, pemetrexed vs. BSC/placebo, pemetrexed + bevacizumab vs. bevacizumab and pemetrexed vs. bevacizumab groups. We were
careful to avoid mixing the groups. Instead of using previous quality assessment tables, we adopted the Cochrane-recommended Cochrane Collaboration’s risk of bias graph to assess the risk of bias and the GRADE system to assess the grading of evidence in the outcome of the meta-analysis to more objectively evaluate the bias risk and the evidence grading of studies. The Cochrane Collaboration’s risk of bias graph revealed that the overall bias of all of the included studies was moderate. Among these studies, two double-blind studies exhibited low bias. The GRADE system revealed that the overall grading of evidence in the gemcitabine vs. BSC/observation group was "MODERATE", and the pemetrexed vs BSC ± placebo group exhibited a "HIGH" rating. The pemetrexed + bevacizumab vs. bevacizumab group and pemetrexed vs bevacizumab group exhibited "LOW" grades.

In the gemcitabine vs. BSC/observation group, gemcitabine significantly improved PFS (HR = 0.62, p = 0.000, I² = 0.0%) but did not significantly improve OS (HR = 0.91, p = 0.314, 

| Study                                      | RR (95% CI)     | Weight |
|--------------------------------------------|-----------------|--------|
| gemcitabine VS BSC/observation             |                 |        |
| Belani2010                                  | 3.53 (1.76, 7.09) | 9.33   |
| Perol2012                                   | 5.86 (3.22, 10.67) | 10.36  |
| Subtotal (I-squared = 14.6%, p = 0.279)    | 4.70 (2.87, 7.69) | 19.69  |
|                                          |                 |        |
| pemetrexed VS BSC+/placebo                  |                 |        |
| Ciuleanu2009                                | 3.92 (1.99, 7.69) | 9.56   |
| Paz-Ares2012                                | 5.05 (2.94, 8.68) | 11.00  |
| Mubarak2012                                 | 0.96 (0.27, 3.47) | 4.89   |
| Subtotal (I-squared = 63.8%, p = 0.063)    | 3.27 (1.56, 6.83) | 25.45  |
|                                          |                 |        |
| pemetrexed+bevacizumab VS bevacizumab       |                 |        |
| Barles2014                                  | 1.38 (1.16, 1.64) | 14.57  |
| Patel2013                                   | 1.18 (1.10, 1.27) | 15.00  |
| Subtotal (I-squared = 62.1%, p = 0.104)    | 1.25 (1.08, 1.45) | 29.57  |
|                                          |                 |        |
| pemetrexed VS bevacizumab                   |                 |        |
| Zinner2015                                  | 0.94 (0.82, 1.08) | 14.75  |
| Galetta2015                                 | 0.57 (0.32, 1.02) | 10.54  |
| Subtotal (I-squared = 65.7%, p = 0.088)    | 0.79 (0.49, 1.29) | 25.29  |
|                                          |                 |        |
| Overall (I-squared = 93.7%, p = 0.000)     | 1.84 (1.31, 2.60) | 100.00 |

NOTE: Weights are from random effects analysis

Fig 5. Meta-analysis results of grade 3–4 AEs.
doi:10.1371/journal.pone.0149247.g005
The grades of evidence of PFS and OS in the GRADE system were "MODERATE" and were attributed to the studies of Brodowicz [6] and Belani [14] (these studies did not describe whether they were open-label or double-blind) and the Perol study [7] (this was an open-label trial). Thus, all of the three studies displayed bias in allocation concealment and
blinding performance. Regarding histology, all of three studies were NSCLC, include adenocarcinoma, squamous cell carcinoma, large cell carcinoma and other type. In subgroup analysis of the Perol [7] study, different benefits were not noted between the squamous and non-squamous sub-types, all of the remaining subgroups exhibited a benefit in PFS, but the benefit was more obvious in patients who had an objective response to induction treatment. The Brodowicz [6] and Belani [14] studies did not conduct a subgroup analysis. As for performance status (PS), in Belani’s study[14], only 36% of patients had a Eastern Cooperative Oncology Group (ECOG)≤1 at the time of randomization, but this data in Perol’s study [7] was 94.5% (292/309), and in Brodowicz’s study [6] 48.1% (99/206) of patients had a Karnofsky performance status (KPS)>80 scores. Regarding the grade 3–4 AEs, gemcitabine therapy significantly increased the grade 3–4 AEs (HR = 4.7, p = 0.000), and the effect was distinct. Only one study showed an RR > 2, and another study showed an RR > 5, thus increasing the scores of the evidence grade. Thus, the grade of evidence was "HIGH". The most common AE was neutropenia with an incidence of 13.3 to 20.8% [7, 14]. Our results were consistent with those of Zhang [13], in which the pooled HR of PFS was 0.53 (0.43–0.65) and that of OS was 0.88 (0.74–1.04).

In the pemetrexed vs. BSC±placebo group, pemetrexed improve both the PFS (HR = 0.54, p = 0.000; I² = 59.8%, p = 0.083) and OS (HR = 0.75, p = 0.000, I² = 0.0%). The grades of evidence for PFS and OS were both "HIGH", which were attributed to the two primary studies being double-blind trials with no bias in allocation concealment and blinding performance. Our sensitivity analysis revealed that the heterogeneity in PFS originated from the Ciuleanu [8] study. In that study, the HR of PFS for all NSCLC cases was 0.50 (0.42–0.61). When this HR was incorporated into this meta-analysis, the pooled HR was 0.55 (0.47–0.65, p = 0.000; I² = 11%, p = 0.325). Additionally, regarding the squamous histology cases, the HR of PFS was 0.69 (0.49–0.98), and the HR of OS was 1.07 (0.77–1.50). In addition, the OS advantage disappeared. No additional subgroup data were available from the Ciuleanu [8] and Mubarak [26] studies, so we were unable to perform a subgroup meta-analysis to further assess the heterogeneity. In the Paz-Ares [9, 10] study, PFS and OS were improved in all of the subgroups. In patients with a complete response (CR) or partial response (PR), the HR in the CR or PR was 0.48. In patients with stable disease (SD), the HR was 0.74. Regarding grade 3–4 AEs, pemetrexed significantly increased the AEs (HR = 3.27, p = 0.002; I² = 63.8%, p = 0.063). Because the sample size of the Mubarak [26] study was too small, after we excluded this study, the heterogeneity was absent (I² = 0.0%), and the HR was 4.59. The evidence grade was also "HIGH" because one study had an RR > 2 and another study had an RR > 5, thus increasing the evidence grade scores. The most common grade 3–4 AEs were fatigue (5%), neutropenia (3–4%), anemia (3–4%) [8, 9, 10].

In the pemetrexed + bevacizumab vs. bevacizumab group, the pemetrexed + bevacizumab group almost exhibited significantly improved PFS (HR = 0.71, p = 0.051; I² = 81.5%, p = 0.020), but no obvious change in OS was noted (HR = 0.98, p = 0.744, I² = 0.0%), thus significantly increasing the incidence of grade 3-4AEs (HR = 1.25, p = 0.002, I² = 62.1%, p = 0.104). The evidence grade of PFS and grade of 3–4 AEs was "LOW", which could be attributed to the fact that all of the studies were open label trials and the large heterogeneity. However, regarding OS, the evidence grade was elevated to "MODERATE" because no heterogeneity was noted. The sensitivity analysis indicated that the heterogeneity in PFS and grade 3–4 AEs both originated from the Patel [20] study. This study lacked subgroup data to perform a subgroup meta-analysis, and which was limited in its design, which did not allow separate evaluation of the contribution of maintenance therapy to the efficacy outcomes. In the pemetrexed vs. bevacizumab group, pemetrexed did not exhibit an obvious change in PFS (HR = 0.96, p = 0.752; I² = 35.8%, p = 0.212) or OS (HR = 0.98, p = 0.744, I² = 0.0%) but
exhibited a slight trend to reduce grade 3–4 AEs (HR = 0.79, p = 0.343, I² = 65.7, p = 0.088).

The evidence grades of PFS and OS were "MODERATE". This result was attributed to the fact that these trials were open label, but large heterogeneity was not noted. However, regarding grade 3–4 AEs, the evidence grade decreased to "LOW" due to the obvious heterogeneity. The sensitivity analysis indicated that the heterogeneity was derived from the Zinner [27] study.

The Karayama [29] study assessed pemetrexed versus docetaxel in maintenance therapy after induction treatment with pemetrexed and carboplatin. The primary endpoint was survival without toxicity, and survival in the pemetrexed group (median: 20.8 months) was significantly increased compared with the docetaxel group (median: 0.5 months, HR = 0.36). However, the docetaxel group (8.2 months) exhibited an increased median PFS compared with the pemetrexed group (4.1 months), and the HR was 0.56 (p = 0.084). The OS in the pemetrexed group was increased (20.6 months) compared with the docetaxel group (19.9 months), and the HR was 0.79 (p = 0.622). Because this group only included one study, we did not use the GRADE system to assess the level of evidence.

Association with social economics. In recent years, the increasing emphasis on healthcare spending has placed growing pressure on policymakers. In the United States, US$2.8 trillion per year is spent on healthcare, a level that outpaced the gross domestic product (GDP) [30]. Several cost-effective studies of maintenance pemetrexed have been conducted according to the JMEN trial in the United States, United Kingdom, Switzerland, and Japan. The incremental cost-effectiveness ratio (ICER) per life year gained of maintenance pemetrexed was US$122,371 in the US (just below the accepted US standard of renal hemodialysis with an ICER of US$129,090) [31]. An estimate of ICER was US$139,000 in Switzerland (above the nationally accepted willingness-to-pay threshold in Switzerland of €72,000) [32], US$72,000 in the United Kingdom [33], and US$150,115 in Japan (above the Japanese threshold of US$43,478).

Limitations

At the original study level: (1) The Belani [14] study was only an abstract, and the patient population had a worse PS at the time of randomization, which maybe induced a negative outcomes. (2) All of the open-label trials had a bias in allocation concealment and blinding performance. (3) The limitation in the designs of the Patel (2013) [20], Zinner (2015) [27] and Galetta (2015) [28] studies involves not separately evaluating the contribution of maintenance therapy to the efficacy outcomes. However, the other RCTs confirmed that the PFS or OS of pemetrexed was consistent in induction + maintenance therapy compared with maintenance therapy alone [9, 10].

2. At the systematic review and meta-analysis level: (1) We only searched the PubMed, Embase, Cochrane library, ASCO, ESMO, and NCCN databases and cannot account for other potentially relevant articles that were published in any other database. (2) Only a limited number of studies were included in the separate-group meta-analysis. (3) In the pemetrexed VS BSC ± placebo group, the Ciuleanu [8] study involved switch maintenance, whereas the Paz-Ares [9, 10] study involved continuation maintenance. Although they both revealed a change in PFS and OS, other differences remain unknown. (4) Sufficient subgroup data were not available to perform subgroup analysis to further explore heterogeneity.

Conclusions

In our article, we confirmed that gemcitabine significantly improved PFS compared with BSC, pemetrexed significantly improved PFS and OS compared with BSC ± placebo, and pemetrexed + bevacizumab approached a significantly improved PFS compared with bevacizumab alone. The incidence of grade 3–4 AEs was significantly increased in the maintenance therapy
arm compared with the control arm. Additional trials are required to confirm the impact of pemetrexed + bevacizumab vs. bevacizumab and pemetrexed vs. bevacizumab. In particular, randomized, controlled double-blind trials are required. Randomized, controlled double-blind trials are also needed for gemcitabine vs. BSC studies. In pemetrexed + bevacizumab vs. bevacizumab or pemetrexed vs. bevacizumab studies, the contribution of maintenance therapy to the outcomes should be separately evaluated. Finally, regarding the socioeconomic impact, the problems of maintenance therapy must identify new solutions.

Supporting Information

S1 PRISMA Checklist. PRISMA 2009 Checklist for this article.
(DOC)

S1 Protocol. Protocol for this systematic review.
(DOC)

Acknowledgments

We thank Jianquan Yang (Department of oncology, Nanchong Center Hospital) for help us draw the Cochrane-recommended Cochrane Collaboration’s risk of bias graph.

Author Contributions

Conceived and designed the experiments: XH WH. Performed the experiments: XH KP X. Feng SW. Analyzed the data: X. Fu CG. Contributed reagents/materials/analysis tools: XH. Wrote the paper: XH KP.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA cancer J Clin, 2011, 61(2): 69–90. doi: 10.3322/caac.20107 PMID: 21296855

2. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251–6266. doi: 10.1200/JCO.2009.23.5622 PMID: 19917871

3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92–8. PMID: 11784875

4. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335–43. PMID: 11870177

5. Correale P, Miano ST, Remondo C, Migali C, Rotundo MS, Macri P, et al. Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocytemacrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther 2009; 8:497–502. doi: 10.4161/cbt.8.6.7593 PMID: 19242101

6. Brodowicz T, Krzakowski M, Zwitter M, et al.; Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenancegemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006; 52 (2): 155–163. PMID: 16569462

7. Péro M, Chouaid C, Péro D, Barlesi F, Gervais R, Westeel V, et al. Randomized, phase III study of gemcitabine or erlotinib maint- enance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy inadvanced non–small–cell lung cancer. J Clin Oncol. 2012, 1; 30(28):3516–24. PMID: 22949150

8. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009; 374:1432–40. doi: 10.1016/S0140-6736(09) 61497-5 PMID: 19767093
9. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012; 13(3):247–55. doi: 10.1016/S1470-2045(12)70063-3 PMID: 22341744

10. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P, et al. PARAMOUNT: F- n al overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non- squamous non-small-cell lung cancer. J Clin Oncol. 2013, 10; 31(23):2885–902. doi: 10.1200/JCO.2012.47.1102 PMID: 23835707

11. Behera M, Owonikoko TK, Chen Z, Kono SA, Khuri FR, Belani CP, et al. Single agent maint enance therapy for advanced stage non- mall cell lung cancer: a meta-analysis. Lung Cancer. 2012; 77 (2):331–8. PMID: 22546678

12. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009, 10; 27 (20):3277–83.

13. Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, et al. Maintenance therapy with continuous o- r switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis Chest. 2011, 140 (1):117–26. doi: 10.1378/chest.10-2745 PMID: 21436247

14. Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, et al. Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small-cell lung cancer (NSCLC) [abstract 7506]. J Clin Oncol. 2010; 28 (suppl): 15S.

15. Pérol M, Zalcman G, Monnet I, et al. Final results from the IFCT-GFPC 0502 phase III study: maintenance progression-free survival results of the phase III study of maintenance pemetrexed versus placebo immediately after cisplatin-gemcitabine induction chemotherapy (CT), with predefined second-line treatment [abstract]. Ann Oncol. 2010; 21 (suppl 8): viii 124.

16. Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Erlotinib and pemetrexed as maintenance therapy for advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2013, 10; 31(23):2895--2902. doi: 10.1200/JCO.2012.47.1102 PMID: 23198220

17. Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Erlotinib and pemetrexed as maintenance therapy for advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2013, 10; 31(23):2895--2902. doi: 10.1200/JCO.2012.47.1102 PMID: 23198220

18.手島 D, 高橋 M, 鈴木 R, 高倉 R, 赤石 R, 武田 N, 八木原 T, et al. Maintenance therapy with bevacizumab and pemetrexed versus placebo plus best supportive care after induction therapy with carboplatin and pemetrexed (FPC-MAB) in patients with advanced non-small-cell lung cancer: A randomized phase III trial. Ann Oncol. 2010; 21(1):104--112.

19. Patil JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab fol lowed by maintenance beva- cizumab in patients with stage IIIb or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013, 1; 31 (34): 4349--57. doi: 10.1200/JCO.2012.47.9626 PMID: 24145346

20. Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. doi: 10.1136/bmj.b2700 PMID: 19622552

21. Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, et al. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin in patients with stage IIIb or IV nonsquamous non-small-cell lung cancer (AVAPERL): final overall survival results of a phase III study. J Clin Oncol. 2013, 1; 31 (34): 4349--57. doi: 10.1200/JCO.2012.47.9626 PMID: 24145346

22. Karayama M, Inui N, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, et al. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin in patients with stage IIIb or IV nonsquamous non-small-cell lung cancer: a randomized, phase II study. Cancer Chemother Pharmacol. 2013; 72(2):445--52. doi: 10.1007/s00280-012-2218-6 PMID: 23807323

23. Higgins JPT, Green S. Cochrane Handbook for systematic reviews of Interventions Version 5.1.0 [updated March 2011]. The cochraneCollaboration, 2011. Available: www.cochrane-handbook.org.
26. Deeks JJ, Altman DG. Cochrane handbook for systematic reviews of interventions Version 5.1. 0 [updated March 2011] Chapter 9: Analysing data and undertaking meta-analyses. 2011.

27. Mubarak N, Gaafar R, Shehata S, Hashem T, Abigera D, Azim HA, et al. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus bestsupportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer. 2012; 24; 12: 423. doi: 10.1186/1471-2407-12-423 PMID: 23006447

28. Zinner RG, Obasaju CK, Spigel DR, Weaver RW, Beck JT, Waterhouse DM, et al. PRONOUNCCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2015; 10(1):134–42. doi: 10.1097/JTO.0000000000000366 PMID: 25371077

29. Galetta D, Cinieri S, Pisconti S, Gebbia V, Morabito A, Borsellino N, et al. Cisplatin/ Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/ Paclitaxel/ Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. Clin Lung Cancer. 2015; 16(4):262–73. doi: 10.1016/j.cllc.2014.12.002 PMID: 25582493

30. Emanuel E, Tanden N, Altman S, Armstrong S., Berwick D, De Brantes F. et al. A systemic approach to containing health care spending. N Engl J Med 2012, 367: 949–954. doi:10.1056/NEJMsb1205901 PMID: 22852883

31. Lee C, Chertow G, Zenios S. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009, 12: 80–87. doi: 10.1111/j.1524-4733.2008.00401.x PMID: 19911442

32. Matter-Walstra K, Joerger M, Kuhnel U, Szucs T, Pestalozzi B, and Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous non-small-cell lung cancer from the perspective of the Swiss health care system. Value Health 2012, 15: 65–71. doi: 10.1016/j.jval.2011.08.1737 PMID: 22264973

33. Learn P, Bach P (2010) PEM and the cost of multicycle maintenance. J Thorac Oncol 5: 1111–1112. doi: 10.1097/JTO.0b013e3181e7c425 PMID: 20661082